Several of the chemotherapeutics were reported to kill selectively colon cancer KRAS mutant cells, in particular drugs targeting DNA topoisomerases, such as camptothecin derivatives and anthracyclines such as doxorubicin [79]. This evidence concerns the gene KRAS and malignant colon neoplasm.